Esophageal Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Growth and Demand Forecast to 2023
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
GLOBAL INDUSTRY INSIGHT:<br />
<strong>Esophageal</strong> <strong>Cancer</strong> <strong>Therapeutics</strong> <strong>Market</strong> - <strong>Epidemiology</strong> <strong>Analysis</strong>,<br />
<strong>Therapy</strong>, <strong>Growth</strong> <strong>and</strong> Dem<strong>and</strong> <strong>Forecast</strong> <strong>to</strong> <strong>2023</strong>
<strong>Esophageal</strong> <strong>Cancer</strong> <strong>Therapeutics</strong> <strong>Market</strong> <strong>Analysis</strong>, Development<br />
<strong>and</strong> <strong>Forecast</strong> <strong>to</strong> <strong>2023</strong><br />
Global esophageal cancer therapeutics market is expected <strong>to</strong> witness significant growth with<br />
an increasing awareness regarding cancer treatment <strong>and</strong> technological advancements. Also, high<br />
dem<strong>and</strong> for safe <strong>and</strong> effective medications <strong>and</strong> rising prevalence of cancer are driving the growth of<br />
the global market. The regula<strong>to</strong>ry bodies such as USFDA, EMA are supporting the growth of the<br />
global market by providing funding, designations <strong>and</strong> grants for speeding up the drug development<br />
process.<br />
Explore Report at: https://www.psmarketresearch.com/market-analysis/esophagealcancer-therapeutics-market<br />
<strong>Esophageal</strong> cancer involves formation of malignant cells in the tissues of the esophagus. Esophagus<br />
is a muscular tube that enable food <strong>and</strong> liquids <strong>to</strong> move from the throat <strong>to</strong> the s<strong>to</strong>mach. The main<br />
types of esophageal cancer are adenocarcinoma <strong>and</strong> squamous cell carcinoma. Adenocarcinoma<br />
forms in cells that produce <strong>and</strong> release mucus <strong>and</strong> other fluids. Squamous cell carcinoma forms in<br />
flat cells lining the esophagus. <strong>Esophageal</strong> squamous cell carcinoma includes heavy alcohol<br />
consumption <strong>and</strong> smoking as major risk fac<strong>to</strong>rs, with gastroesophageal reflux disease <strong>and</strong> Barrett<br />
esophagus further contributing as the risk fac<strong>to</strong>rs of esophageal adenocarcinoma. <strong>Esophageal</strong><br />
cancer has no early signs or symp<strong>to</strong>ms; therefore, an advanced stage diagnosis is difficult.<br />
Some of the major drivers for the global esophageal cancer therapeutics market include<br />
combination therapies, treatment advancements, increasing number of regula<strong>to</strong>ry approvals for<br />
esophageal cancer <strong>and</strong> a rise in the number of cancer treatment centers. Moreover, the launch of<br />
new drug therapies for esophageal cancer is expected <strong>to</strong> contribute as a key market driver in the<br />
near future. Also with a dense pipeline, many new drug c<strong>and</strong>idates are expected <strong>to</strong> enter the global<br />
esophageal cancer therapeutics market. Safety concerns <strong>and</strong> efficacy of the treatment are the<br />
major fac<strong>to</strong>rs that can hinder the market growth over the forecast period. Other fac<strong>to</strong>rs hampering<br />
the market growth include low availability of drugs commercially <strong>and</strong> high cost of therapy for the<br />
treatment of esophageal cancer.<br />
Request for Table of Content at: https://www.psmarketresearch.com/marketanalysis/esophageal-cancer-therapeutics-market/<strong>to</strong>c-sample<br />
The pipeline of the esophageal cancer contains 69 drug c<strong>and</strong>idates, with five c<strong>and</strong>idates in Phase<br />
III. These drug c<strong>and</strong>idates are expected <strong>to</strong> enter the market in future, leading <strong>to</strong> a drastic shift in<br />
the global esophageal cancer therapeutics market.<br />
© P&S <strong>Market</strong> Research. All rights reserved 2
<strong>Esophageal</strong> <strong>Cancer</strong> <strong>Therapeutics</strong> <strong>Market</strong> <strong>Analysis</strong>, Development<br />
<strong>and</strong> <strong>Forecast</strong> <strong>to</strong> <strong>2023</strong><br />
Genentech, Inc. markets Trastuzumab (Herceptin) in combination with cisplatin <strong>and</strong> a<br />
fluoropyrimidine (either capecitabine or 5-fluorouracil), for the treatment of patients with HER2-<br />
overexpressing metastatic gastric or gastroesophageal (GE) junction adenocarcinoma who were not<br />
treated for metastatic disease prior.<br />
Certain chemotherapy medications such as Doxorubicin, Bleomycin, Vinblastine, Dacarbazine,<br />
Chlorambucil, Procarbazine Prednisolone, Mustine, Vincristine, E<strong>to</strong>poside, Cyclophosphamide,<br />
Gemcitabine, Cisplatin <strong>and</strong> Cytarabine are well established as a conventional method.<br />
Immunotherapy, combination therapy, monoclonal antibodies <strong>and</strong> steroids have also been showing<br />
good results for the treatment of esophageal cancer.<br />
Browse Other Related Report at: https://www.psmarketresearch.com/industryreport/pharmaceuticals<br />
Some of the key players operating in the global esophageal cancer therapeutics market include<br />
Genentech, Inc., Sanofi-Aventis, Eli Lilly <strong>and</strong> Company, Ono Pharmaceutical Co., Ltd., Merck & Co.,<br />
Inc., Johnson & Johnson Pharmaceutical Research & Development, LLC, Gilead Sciences, <strong>and</strong><br />
Bris<strong>to</strong>l-Myers Squibb, among others.<br />
About P&S <strong>Market</strong> Research<br />
P&S <strong>Market</strong> Research is a market research company, which offers market research <strong>and</strong> consulting<br />
services for various geographies around the globe. We provide market research reports, industry<br />
forecasting reports, business intelligence, <strong>and</strong> research based consulting services across different<br />
industry/business verticals.<br />
As one of the <strong>to</strong>p growing market research agency, we’re keen upon providing market l<strong>and</strong>scape<br />
<strong>and</strong> accurate forecasting. Our analysts <strong>and</strong> consultants are proficient with business intelligence <strong>and</strong><br />
market analysis, through their interaction with leading companies of the concerned domain. We<br />
help our clients with B2B market research <strong>and</strong> assist them in identifying various windows of<br />
opportunity, <strong>and</strong> framing informed <strong>and</strong> cus<strong>to</strong>mized business expansion strategies in different<br />
regions.<br />
© P&S <strong>Market</strong> Research. All rights reserved 3
<strong>Esophageal</strong> <strong>Cancer</strong> <strong>Therapeutics</strong> <strong>Market</strong> <strong>Analysis</strong>, Development<br />
<strong>and</strong> <strong>Forecast</strong> <strong>to</strong> <strong>2023</strong><br />
Contact:<br />
Kundan<br />
Manager – Client Partner<br />
347, 5th Ave. #1402<br />
New York City, NY - 10016<br />
Toll-free: +1-888-778-7886 (USA/Canada)<br />
Email: enquiry@psmarketresearch.com<br />
Web: https://www.psmarketresearch.com<br />
Connect with us: LinkedIn | Twitter | Google + | Facebook<br />
© P&S <strong>Market</strong> Research. All rights reserved 4
Change language